LUNG DRUG DELIVERY WITH CARBON DIOXIDE AEROSOL INHALERS

使用二氧化碳气溶胶吸入器进行肺部药物输送

• 批准号: 6294877
• 负责人: Brian N Hansen
• 金额: $ 10万
• 依托单位: AEROPHASE, INC.
• 依托单位国家: 美国
• 财政年份: 2001
• 资助国家: 美国
• 起止时间: 2001-03-09 至 2001-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6294877
• 关键词: aerosols; carbon dioxide; dosage; dosage forms; drug delivery systems; drug design /synthesis /production; inhalation drug administration; technology /technique development

DESCRIPTION (Adapted from the Investigator's Abstract): The chlorofluorocarbon (CFC) propellants currently being used in metered dose inhalers for pulmonary drug delivery are being phased out due to their high ozone depletion potential. An international pharmaceutical industry consortium has proposed that the zero-ozone depletion potential hydrofluoroalkane (HFA) propellants will replace CFCs in metered dose inhalers. There remain, however, crucial reasons to find other drug aerosolization alternatives. Potential problems with the HFA propellants include toxicity, incompatibility with devices, incompatibility with FDA approved inhaler surfactants and reduced bioavailability of some drugs. The investigators have patented a method for the pulmonary aerosol delivery of pharmaceuticals using supercritical fluid carbon dioxide as an inhaler propellant, and have demonstrated its potential usefulness in vivo in several laboratory studies. The investigators have designed a number of inhaler prototypes that use carbon dioxide as a propellant and are seeking funding for additional research and development of these devices. This technology has several advantages including zero-ozone depletion potential propellant, low toxicity of carbon dioxide, and the ability to administer to the lungs lipophilic drugs which cannot currently be delivered by any other method. The investigators propose to improve and thoroughly test a new form of metered dose inhaler which uses carbon dioxide as a propellant. PROPOSED COMMERCIAL APPLICATION: 1. This ozone-friendly technology may replace existing MDI propellants. 2. Aerosol delivery of antibiotics may reduce death from pneumonia. 3. This inhaler may prove to be better than needle injection of insulin. 4. This is an excellent surfactant delivery system to reduce acute lung injury. 5. This may deliver drugs that cannot be administered by any other method.

描述（改编自研究者摘要）：氯氟烃 (CFC) 推进剂目前用于肺部疾病定量吸入器 由于其高臭氧消耗潜力，药物输送正在被逐步淘汰。 一个国际制药工业联盟提议 零臭氧消耗潜值氢氟烷（HFA）推进剂将取代 计量吸入器中的氟氯化碳。然而，仍然有一些重要的理由需要找到 其他药物雾化替代品。 HFA 的潜在问题 推进剂包括毒性、与装置不相容、不相容 含有 FDA 批准的吸入器表面活性剂，并降低了某些物质的生物利用度 药物。研究人员已获得肺部气溶胶方法的专利 使用超临界流体二氧化碳作为药物输送 吸入器推进剂，并已证明其在体内的潜在用途 多项实验室研究。研究人员设计了多种吸入器 使用二氧化碳作为推进剂的原型机正在寻求资金 这些设备的额外研究和开发。这项技术有 多种优点包括零臭氧消耗潜势推进剂、低 二氧化碳的毒性以及向肺部给药的能力 目前无法通过任何其他方法递送的亲脂性药物。这 研究人员建议改进并彻底测试一种新形式的计量剂量 使用二氧化碳作为推进剂的吸入器。 拟议的商业应用： 1. 这种对臭氧层友好的技术可能会取代现有的MDI推进剂。 2. 抗生素气雾剂可减少肺炎死亡。 3. 这种吸入器可能被证明比针头注射胰岛素更好。 4.这是一种优秀的表面活性剂输送系统，可减少急性肺损伤。 5. 这可能会输送无法通过任何其他方法施用的药物。